164 related articles for article (PubMed ID: 18972468)
1. Small-molecule inhibitors of PDK1.
Peifer C; Alessi DR
ChemMedChem; 2008 Dec; 3(12):1810-38. PubMed ID: 18972468
[TBL] [Abstract][Full Text] [Related]
2. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.
Najafov A; Sommer EM; Axten JM; Deyoung MP; Alessi DR
Biochem J; 2011 Jan; 433(2):357-69. PubMed ID: 21087210
[TBL] [Abstract][Full Text] [Related]
3. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.
Feldman RI; Wu JM; Polokoff MA; Kochanny MJ; Dinter H; Zhu D; Biroc SL; Alicke B; Bryant J; Yuan S; Buckman BO; Lentz D; Ferrer M; Whitlow M; Adler M; Finster S; Chang Z; Arnaiz DO
J Biol Chem; 2005 May; 280(20):19867-74. PubMed ID: 15772071
[TBL] [Abstract][Full Text] [Related]
4. 3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner.
Gagliardi PA; di Blasio L; Orso F; Seano G; Sessa R; Taverna D; Bussolino F; Primo L
Neoplasia; 2012 Aug; 14(8):719-31. PubMed ID: 22952425
[TBL] [Abstract][Full Text] [Related]
5. Modulation of PI3K/PTEN Pathway Does Not Affect Catalytic Activity of PDK1 in Jurkat Cells.
Yang KJ; Piao L; Shin S; Shin SY; Li Y; Lee H; Tran Q; Park J; Hong S; Brazil DP; Hemmings BA; Kim SH; Park J
Anticancer Res; 2017 Oct; 37(10):5415-5423. PubMed ID: 28982851
[TBL] [Abstract][Full Text] [Related]
6. Targeting PDK1 in cancer.
Raimondi C; Falasca M
Curr Med Chem; 2011; 18(18):2763-9. PubMed ID: 21568903
[TBL] [Abstract][Full Text] [Related]
7. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
Zhang X; Zhong S
Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line.
Arico S; Pattingre S; Bauvy C; Gane P; Barbat A; Codogno P; Ogier-Denis E
J Biol Chem; 2002 Aug; 277(31):27613-21. PubMed ID: 12000750
[TBL] [Abstract][Full Text] [Related]
9. Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors.
Chen T; Sorna V; Choi S; Call L; Bearss J; Carpenter K; Warner SL; Sharma S; Bearss DJ; Vankayalapati H
Bioorg Med Chem Lett; 2017 Dec; 27(24):5473-5480. PubMed ID: 29150397
[TBL] [Abstract][Full Text] [Related]
10. For a PDK1 inhibitor, the substrate matters.
Knight ZA
Biochem J; 2011 Jan; 433(2):e1-2. PubMed ID: 21175429
[TBL] [Abstract][Full Text] [Related]
11. Development of high-throughput TR-FRET and AlphaScreen assays for identification of potent inhibitors of PDK1.
Xu Z; Nagashima K; Sun D; Rush T; Northrup A; Andersen JN; Kariv I; Bobkova EV
J Biomol Screen; 2009 Dec; 14(10):1257-62. PubMed ID: 19822882
[TBL] [Abstract][Full Text] [Related]
12. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma.
Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA
Oncogene; 2014 Aug; 33(34):4330-9. PubMed ID: 24037523
[TBL] [Abstract][Full Text] [Related]
13. Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase.
Schulze JO; Saladino G; Busschots K; Neimanis S; Süß E; Odadzic D; Zeuzem S; Hindie V; Herbrand AK; Lisa MN; Alzari PM; Gervasio FL; Biondi RM
Cell Chem Biol; 2016 Oct; 23(10):1193-1205. PubMed ID: 27693059
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme.
Sestito S; Nesi G; Daniele S; Martelli A; Digiacomo M; Borghini A; Pietra D; Calderone V; Lapucci A; Falasca M; Parrella P; Notarangelo A; Breschi MC; Macchia M; Martini C; Rapposelli S
Eur J Med Chem; 2015 Nov; 105():274-88. PubMed ID: 26498573
[TBL] [Abstract][Full Text] [Related]
15. The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01, induces fragmentation: possible role of metalloproteinases.
Alcántara-Hernández R; Hernández-Méndez A; García-Sáinz JA
Eur J Pharmacol; 2014 Oct; 740():88-96. PubMed ID: 25016091
[TBL] [Abstract][Full Text] [Related]
16. Phosphoinositide-dependent protein kinase 1 (PDK1) mediates potent inhibitory effects on eosinophils.
Sturm EM; Parzmair GP; Radnai B; Frei RB; Sturm GJ; Hammer A; Schuligoi R; Lippe IT; Heinemann A
Eur J Immunol; 2015 May; 45(5):1548-59. PubMed ID: 25645675
[TBL] [Abstract][Full Text] [Related]
17. PDK1 inhibitor GSK2334470 synergizes with proteasome inhibitor MG‑132 in multiple myeloma cells by inhibiting full AKT activity and increasing nuclear accumulation of the PTEN protein.
Zhang J; Yang C; Zhou F; Chen X
Oncol Rep; 2018 Jun; 39(6):2951-2959. PubMed ID: 29658600
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis-induced effects of extract from Artemisia annua Linné by modulating PTEN/p53/PDK1/Akt/ signal pathways through PTEN/p53-independent manner in HCT116 colon cancer cells.
Kim EJ; Kim GT; Kim BM; Lim EG; Kim SY; Kim YM
BMC Complement Altern Med; 2017 Apr; 17(1):236. PubMed ID: 28454566
[TBL] [Abstract][Full Text] [Related]
19. PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242.
Yang C; Huang X; Liu H; Xiao F; Wei J; You L; Qian W
Oncotarget; 2017 Jun; 8(24):39185-39197. PubMed ID: 28402933
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
